Clear Street Markets LLC Sells 4,370 Shares of Johnson & Johnson (NYSE:JNJ)

Clear Street Markets LLC decreased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 37.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 7,315 shares of the company’s stock after selling 4,370 shares during the quarter. Clear Street Markets LLC’s holdings in Johnson & Johnson were worth $1,195,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in JNJ. Morton Brown Family Wealth LLC boosted its position in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the period. Goodman Advisory Group LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $39,000. First Bank & Trust increased its holdings in shares of Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares during the period. Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $84,000. Finally, Timber Creek Capital Management LLC increased its holdings in shares of Johnson & Johnson by 225.0% during the 3rd quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock worth $106,000 after purchasing an additional 450 shares during the period. Institutional investors own 67.94% of the company’s stock.

Insider Buying and Selling

In related news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock valued at $40,960,735 over the last ninety days. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $168.31 on Wednesday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm’s 50 day moving average is $175.98 and its 200-day moving average is $171.06. The firm has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.13 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on JNJ shares. Bank of America dropped their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Raymond James lowered their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Finally, SVB Leerink lowered their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.